• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Daily Dose: Atogepant Associated with Reduction in Monthly Migraine Days

News
Article

A daily dose of clinical news on Patient Care you may have missed.

Daily Dose: Distinct Patterns of BP in Early Gestation Predict Hypertensive Disorders / Image Credit: ©New Africa/AdobeStock

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.


On August 4, 2023 we reported on a study published in Lancet Neurology that examined the safety, tolerability, and efficacy of atogepant 30 mg taken twice daily and 60 mg taken once daily.

The study

The randomized, double-blind, placebo-controlled trial was conducted at 142 international sites and enrolled adults aged 18 to 80 years with at least a 1-year history of chronic migraine with age of onset before age 50 years. Investigators randomly assigned eligible participants in 1:1:1 ratio to receive oral atogepant 30 mg twice a day, oral atogepant 60 mg once a day, or placebo for 12 weeks. The study's primary efficacy endpoint was defined as change in monthly migraine days (MMD) from baseline to end of treatment period and was analyzed in the modified intent to treat population. The safety population was comprised of all participants who received at least 1 dose of a study drug or placebo.

The researchers assessed potential participants for eligibility between March 11, 2019, and January 20, 2022, and the final cohort numbered 778. Researchers reported that 84 participants left the trial with the modified intent-to-treat population comprised of 755 participants n (atogepant 30 mg twice a day n=253, atogepant 60 mg once a day n=256, and placebo n=246).

The findings

The investigators reported that change from the baseline MMDs over the 12-week study period was −7.5 (SE 0.4) with atogepant 30 mg twice daily, −6.9 (0.4) with atogepant 60 mg once daily, and −5.1 (0.4) with placebo. The calculated least squares mean difference from placebo was −2.4 with atogepant 30 mg twice daily (95% CI −3.5 to −1.3; adjusted P<.001) and −1.8 with atogepant 60 mg once daily (−2.9 to −0.8; adjusted P=.0009).

Investigators also observed significant reductions in mean number of days a month when acute medication was used as well as clinically significant improvements over placebo in patient reported outcomes.

Authors' commentary

"Atogepant 30 mg twice a day and 60 mg once a day showed clinically relevant reductions in MMDs across 12 weeks in chronic migraine patients. Both atogepant doses were well tolerated, consistent with the known safety profile of atogepant."

Click here for more details.


Related Videos
Primary Care is the Answer to the Migraine Care Gap, Says Headache Specialist
Migraine Management Pearls for Primary Care with Neurologist Jessica Ailani, MD
Migraine-specific therapies belong in primary care setting, Jessica Ailani, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.